The phase 1/2 ResQ133A-NMIBC trial: A study of intravesical recombinant Mycobacterium Bacillus Calmette‑Guérin (rBCG) in BCG‑naïve participants with non‑muscle‑invasive bladder cancer (NMIBC)

The phase 1/2 ResQ133A-NMIBC trial: A study of intravesical recombinant Mycobacterium Bacillus Calmette‑Guérin (rBCG) in BCG‑naïve participants with non‑muscle‑invasive bladder cancer (NMIBC)

Sunday, May 17, 2026 10:44 AM to 10:52 AM · 8 min. (America/New_York)
Hall B, The Square, Learning Lab
Detail
Oncology: Bladder

Registered attendees

Randy Tsai
Randy Tsai
Medical StudentDavid Geffen School of Medicine at UCLA
Scott Flanders
Scott Flanders
VP of Medical AffairsImmunityBio, Inc.
Seth Lerner
Seth Lerner
Vice Chair for Faculty AffairsBaylor College of Medicine Scott Department of Urology

Log in

See all the content and easy-to-use features by logging in or registering!